Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q3 2025 · 10-Q
Revenue$260.00K$260.00K+126.1% vs Q3 2024 Net Income-$10.85M-$10.85MN/M vs Q3 2024 EPS Diluted-$0.34-$0.34N/M vs Q3 2024 Gross Profit$139,000+178.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,626,000N/M Free Cash Flowderived-$5,676,000N/M Margins · derivedGross margin53.5%+10.0 pt vs Q3 2024
Operating margin-4249.2%+7502.9 pt vs Q3 2024
Net margin-4174.6%+7558.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end